1-5 of 5
David C. Turner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)

Brendan C Bender, Chi-Chung Li, Mathilde Marchand, David C. Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Jin, Chunze Li, Shen Yin, Michael C. Wei, Pascal Chanu
Journal: Blood
Blood (2023) 142 (Supplement 1): 2810.
https://doi.org/10.1182/blood-2023-182086
Published: 2023
Journal Articles

New Tocilizumab (TCZ) Dosing Guidance for T-Cell Engaging Bispecific Antibody-Related Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL): Insights from Pooled Clinical Trial Safety Experience and Quantitative Clinical Pharmacology (qCP) Analyses

Candice Jamois, David C. Turner, Leonid Gibiansky, Feifei Li, Nicolas Frey, Jean-Francois Menuet, Leonardo Roque Pereira, Linda Lundberg, Elena Guerini, David John Carlile, James Relf, Michael C. Wei, Antonia Kwan, Susan Grange
Journal: Blood
Blood (2023) 142 (Supplement 1): 1742.
https://doi.org/10.1182/blood-2023-177679
Published: 2023
Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung-Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutierrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Hess, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn
Journal: Blood
Blood (2022) 140 (Supplement 1): 3753–3755.
https://doi.org/10.1182/blood-2022-157729
Published: 2022
Journal Articles

Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Ling-Yuh Huw, Feifei Li, Anton Belousov, Hemanth Ramesha, Christopher R. Bolen, Michael C. Wei, Shen Yin, David C. Turner, Elicia Penuel
Journal: Blood
Blood (2022) 140 (Supplement 1): 6448–6449.
https://doi.org/10.1182/blood-2022-157934
Published: 2022
Journal Articles

Crenolanib is active against models of drug-resistant FLT3-ITD−positive acute myeloid leukemia

Eric I. Zimmerman, David C. Turner, Jassada Buaboonnam, Shuiying Hu, Shelley Orwick, Michael S. Roberts, Laura J. Janke, Abhijit Ramachandran, Clinton F. Stewart, Hiroto Inaba, Sharyn D. Baker
Journal: Blood
Blood (2013) 122 (22): 3607–3615.
https://doi.org/10.1182/blood-2013-07-513044
Published: 2013
Includes: Supplemental data